Health Care & Life Sciences » Pharmaceuticals | Aeolus Pharmaceuticals Inc.

Aeolus Pharmaceuticals Inc. | Income Statement

Fiscal year is October-September. All values USD Thousands.
2012
2013
2014
2015
2016
Sales/Revenue
7,293.00
3,928.00
9,631.00
3,111.00
2,076.00
Gross Income
-
-
9,631.00
-
-
SG&A Expense
9,657.00
6,620.00
9,711.00
5,737.00
5,349.00
EBIT
2,371.00
2,698.00
80.00
2,626.00
3,273.00
Unusual Expense
4,069.00
510.00
-
-
-
Interest Expense
-
-
-
2.00
285.00
Pretax Income
1,698.00
3,208.00
80.00
2,628.00
3,558.00
Consolidated Net Income
1,698.00
3,208.00
80.00
2,628.00
3,558.00
Net Income
1,698.00
3,208.00
80.00
2,628.00
3,558.00
Net Income After Extraordinaries
1,698.00
3,208.00
80.00
2,628.00
3,558.00
Net Income Available to Common
1,698.00
3,208.00
80.00
2,628.00
6,044.00
EPS (Basic)
0.02
0.03
0.00
0.02
0.04
Basic Shares Outstanding
61,593.00
106,554.00
134,667.00
135,883.00
148,668.00
EPS (Diluted)
0.02
0.03
0.00
0.02
0.04
Diluted Shares Outstanding
72,749.00
106,554.00
134,667.00
135,883.00
148,668.00
EBITDA
2,364.00
2,692.00
80.00
2,626.00
3,273.00
Preferred Dividends
-
-
-
-
2,486.00

About Aeolus Pharmaceuticals

View Profile
Address
26361 Crown Valley Parkway
Mission Viejo California 92691
United States
Employees -
Website http://www.aolsrx.com
Updated 07/08/2019
Aeolus Pharmaceuticals, Inc. engages in the business of developing platform of broad-spectrum, catalytic antioxidant compounds that protect healthy tissue from the damaging effects of oxidative stress development of medical countermeasures against biological, chemical and radiological weapons in the U. S. It also develops medical countermeasures for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.